NGM Biopharmaceuticals, Inc   Report issue

For profit Phase 1 Phase 2
Founded: South San Francisco CA United States (2007)

Organization Overview

First Clinical Trial
2013
NCT01776528
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

NGM Biopharmaceuticals | NGM Biopharmaceuticals Australia Pty Ltd | NGM Biopharmaceuticals, Inc

Active Ingredients

Drugs in Phase 2 Trials (4)

aldafermin (13 trials)

ngm621 (3 trials)

ngm707 (1 trial)

pembrolizumab (keytruda) (3 trials)

Drugs in Phase 1 Trials (6)

mk-3655 (2 trials)

ngm120 (2 trials)

ngm395 (1 trial)

ngm438 (1 trial)

ngm831 (1 trial)

pioglitazone (actos) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Atrophy (Phase 2)

Cachexia (Phase 1)

Cholangitis (Phase 2)

Cholangitis, Sclerosing (Phase 2)

Constipation (Phase 2)

Diabetes Mellitus (Phase 2)

Fatty Liver (Phase 2)

Fibrosis (Phase 2)

Geographic Atrophy (Phase 2)

Infections (Phase 2)

Liver Cirrhosis (Phase 2)

Liver Cirrhosis, Biliary (Phase 2)

Non-alcoholic Fatty Liver Disease (Phase 2)

Obesity (Phase 1)

Pancreatic Neoplasms (Phase 1)

Renal Insufficiency (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 24
  • # of Trial APIs: 10